Cost-effectiveness Analysis of PD-1 Inhibitors As Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China: an Economic Evaluation Based on Network Meta-Analysis.
International Journal of Clinical Pharmacy（2024）
Key words
Camrelizumab,Cost-effectiveness,Esophageal squamous cell carcinoma,Nivolumab,Tislelizumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined